Veeva Announces Fiscal 2026 First Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Veeva Systems (VEEV) PT Raised to $304 at BofA Securities
May 29, 2025 5:38 AM EDTBofA Securities analyst Brad Sills raised the price target on Veeva Systems (NYSE: VEEV) to $304.00 (from $254.00) while maintaining a Neutral rating.
The analyst comments "Veeva reported a strong start to FY26, with subscription revenue and normalized billings of $635 million (+19% y/y) and $714... More
Veeva Systems (VEEV) PT Raised to $295 at Stifel
May 29, 2025 5:05 AM EDTStifel analyst David Grossman raised the price target on Veeva Systems (NYSE: VEEV) to $295.00 (from $272.00) while maintaining a Buy rating.
The analyst comments "F1Q revenue significantly outperformed (subscription revenue +19%, +17% total revenue growth), which translated to meaningful billings/margin/EPS outperformance. Both subscription (+19% y/y, 85% of... More
Veeva Systems (VEEV) PT Raised to $210 at Morgan Stanley
May 29, 2025 5:02 AM EDTMorgan Stanley analyst Craig Hettenbach raised the price target on Veeva Systems (NYSE: VEEV) to $210.00 (from $201.00) while maintaining a Underweight rating.
The analyst comments "Why stay Underweight? Veeva deserves credit for navigating through a tumultuous backdrop in Life Sciences that has tripped up... More
